Thera-SAbDab

RUPLIZUMAB

> Structural Summary

Therapeutic	Ruplizumab
Target	CD40LG
Heavy Chain	QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS
Light Chain	DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK
100% seqID Fv Structure	1i9r [Fvs: HL, KM, XY]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	1i9r [Fvs: HL, KM, XY]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-II
Estimated Status (June '19)	Discontinued
Recorded Developmental Technology	na
INN Year Proposed	2000
INN Year Recommended	2001
Companies Involved	Biogen
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Autoimmune disorders, Haemophilia A, Idiopathic thrombocytopenic purpura, Multiple sclerosis, Renal transplant rejection, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]